First of all, the development of pharmaceutical industry is "the needs of people's livelihood"

Source: on February 19, 2016, Premier Li Keqiang of the State Council recently presided over the executive meeting of the State Council to promote the innovation and upgrading of the pharmaceutical industry and better serve the people's livelihood and steady growth He stressed that the development of the pharmaceutical industry is first of all "the needs of the people's livelihood" and also "the needs of development" We should combine accelerating the healthy development of the pharmaceutical industry with deepening the reform of the medical and health system to better serve the people's livelihood and stabilize growth The expression of "benefiting people's livelihood" and "stabilizing growth" reflects the governing concept of "people-oriented", which is not a simple word ordering problem Although the pulling effect on economy is an important indicator to measure the level of industrial development, it is more important to meet the actual needs of the people and provide practical convenience and benefits Medicine relates to the health and safety of the people, which is the most basic demand for people's livelihood First, "benefiting people's livelihood" is exactly what China's national conditions need If people's livelihood is ignored, the development of pharmaceutical industry will lose its most fundamental significance In recent years, the incidence rate and mortality rate of major diseases such as cancer and diabetes are showing a trend of continuous rising and younger, which has become an important factor threatening people's lives and health Relevant reports show that cancer has become the largest cause of death in China, and the death toll accounts for one quarter of the global cancer deaths The prevalence of diabetes in China also soared from 0.67% in 1980 to 9.7% in 2008 and 11.6% in 2013 The huge and urgent demand for people's livelihood calls for a medical industry with temperature At the counter of domestic drugstores, the drugs needed for the treatment of common diseases seem to be full of varieties, but some commonly used drugs and cheap drugs are often in short supply, and the public has complaints from time to time In order to achieve the goal of benefiting people's livelihood, we must first face up to the gap and shortcomings in basic drugs in China Now when people go abroad, they not only go back to carry toilet covers and electric cookers, but also buy cold medicine and band aids This "voting with feet" is enough to warn the domestic pharmaceutical industry to accelerate the transformation of quality improvement The pain point of the masses is the breakthrough point of reform and innovation The pharmaceutical industry should further improve the safety evaluation and product traceability system, strengthen the quality supervision of the whole process, and improve the quality of essential drugs In China, there is a lack of innovation in common drugs, and there is no money to buy drugs for rare diseases such as difficult and miscellaneous diseases The pharmaceutical industry should enhance the research and development capacity of innovative drugs and enhance the self hematopoiesis capacity of enterprises At the same time, pharmaceutical enterprises and R & D institutions need to focus on the urgent needs of the masses, strengthen the R & D innovation of original research drugs and first generic drugs, speed up the industrialization of major drugs with frequent and rare diseases such as tumors, diabetes, cardiovascular and cerebrovascular diseases, and support the international registration and certification of domestic original research drugs and brand generic drugs that have obtained patents Especially for the "first generic drugs", we should speed up the decontamination of "counterfeiting" and re understand the important value and significance of generic drugs People's livelihood is the biggest market The lame duck who ignores or ignores social benefits is doomed to fail in the long run First "benefiting the people's livelihood" and then "stabilizing the growth", so that people can buy and afford high-quality and effective reassuring drugs and medical services to protect the health of the masses, so that the pharmaceutical industry can develop healthily.